IMPACT-AD COVID-19 UPDATE

This is an unprecedented time in our history. The COVID-19 pandemic is impacting our personal and professional lives in extraordinary ways. The health and safety of course applicants, faculty, and staff—and the community at large—are the top priorities of the IMPACT-AD course.

The leadership of the IMPACT-AD course is closely monitoring the COVID-19 situation. We will provide updated course plans as necessary. At this time, the in-person course remains scheduled for September 13-17 in San Diego, CA.

Thank you,
The IMPACT-AD Team

IMPACT-AD

Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD

September 13-17, 2020

San Diego, CA

A comprehensive training program in clinical trials for Alzheimer's disease and related dementias.

Apply Here

Welcome letter from the Course Directors

Thank you for your interest in the IMPACT-AD Course.

Alzheimer’s Disease and Related Disorders (ADRD) are public health crises and critical areas of scientific effort. The National Institutes of Health, Alzheimer’s Association, and other federal, state, and non-profit funders of research are investing heavily in the science of ADRD in an effort to curb the impact of these debilitating, burdensome, and costly disorders. Tremendous advances made in understanding the pathobiology of disease will ultimately have one final pathway to impacting clinical care and public health – randomized controlled clinical trials.

IMPACT-AD was founded to train the next generation of ADRD clinical trialists, to ensure that investments in discovery yield outcomes for patients and families. Our goal is to provide education and tools to establish a national cohort of qualified investigators to guide the field toward improved therapies. Equally importantly, we are focused on diversifying the ADRD trial workforce. This diversity is manifold: it includes the demographic characteristics of investigators (age, race, ethnicity, etc.), but also their specialties (physicians, psychologists, statisticians, etc.), backgrounds (rural, urban, etc.), and career stage or current position (current AD Clinical Trial Consortium (ACTC) site, non-ACTC academic site, non-academic site). IMPACT-AD will be successful if it produces an outstanding, well-trained, diverse, and knowledgeable cohort of collaborative investigators who will carry the mantle of the National Plan to Address AD.

IMPACT-AD will leverage the outstanding collection of investigators, including members of the ACTC and beyond. National and international leaders in ADRD trials will gather annually to provide a unique, interactive, cutting edge educational experience in ADRD trials. We offer two tracks for those interested in advancing their careers in ADRD trials.

We thank you for your interest in the course and wish you luck on your application.

Sincerely,

Rema Raman, PhD

IMPACT-AD Co-Director

Joshua Grill, PhD

IMPACT-AD Co-Director

Course Tracks

Professionals Track

This track seeks applications from individuals with at least 2 years of experience in ADRD research and/or clinical trials (in a broad variety of roles including, but not limited to clinicians, study coordinators, psychometricians, and other study professionals) who wish to further their knowledge and advance their careers in ADRD trials (2.5 days).

Fellowship Track

This track seeks applications from individuals seeking to serve as Principal Investigators in ADRD trials and offers mentored training in protocol development. Applications are open to individuals in their last year of doctoral training, currently in fellowship or postdoctoral training, faculty members or the equivalent positions (4.5 days).

Course Details

Goals of the Course

To provide junior investigators with a unique, comprehensive, and active learning experience in ADRD trials.

This will be accomplished by leveraging the full infrastructure and expertise of the Alzheimer’s Clinical Trials Consortium (ACTC) to enable a diverse range of clinicians, scientists and researchers to receive modern and robust training on ADRD clinical trials.

About